Celltrion, Inc.

Equities

A068270

KR7068270008

Biotechnology & Medical Research

End-of-day quote Korea S.E. Other stock markets 16/03/2026			5-day change	1st Jan Change
200,000.00 ^KRW	-2.68%		-1.96%	+10.50%

08:00am	Global Oil Price Decline, AI-led Blue Chip Stock Gains Push South Korean Markets Higher for Second Day	MT
04:07am	Celltrion Launches Anti-Inflammatory Drug Biosimilar in US; Shares Rise 3%	MT

Tranche Update on Celltrion, Inc.'s Equity Buyback Plan announced on May 20, 2025.

Published on 06/26/2025 at 08:21 am BST

S&P Capital IQ

CELLTRION, INC.

-2.68%

From May 20, 2025 to June 24, 2025, the company has repurchased 629,118 shares, representing 0.27% for KRW 99,999.93 million. With this, the company has completed the repurchase of 629,118 shares, representing 0.27% for KRW 99,999.93 million under the buyback announced on May 20, 2025.

Latest news about Celltrion, Inc.

08:00am	Global Oil Price Decline, AI-led Blue Chip Stock Gains Push South Korean Markets Higher for Second Day	MT
04:07am	Celltrion Launches Anti-Inflammatory Drug Biosimilar in US; Shares Rise 3%	MT
02:43am	Celltrion Secures Pharmaceutical Manufacturing Contract; Shares Rise 3%	MT
03-16	Celltrion Inc Announces U S Availability Of AVTOZMA® (tocilizumab-anoh) Subcutaneous (SC) Formulation	CI
03-16	Celltrion announces U.S. availability of Avtozma® (tocilizumab-anoh) subcutaneous (SC) formulation	RE
03-11	Bargain-Hunting Drives South Korea's Kospi Higher for a Second Day; Celltrion Adds 1% on New Biosimilar Launch in Europe	MT
03-11	Celltrion Launches Chronic Autoimmune Disease Drug in Europe; Shares Rise 3%	MT
03-09	Celltrion Expands Treasury Share Cancellation	MT
02-05	CVS Health to drop Amgen and Lilly's bone disease treatments from some drug lists (February 5)	RE
01-30	Celltrion Launches Autoimmune Drug Aptozma in Europe	MT
01-14	Celltrion Presents Innovative Drug Pipeline and U.S. Manufacturing and R&D Expansion Strategy At the 44Th Annual J.P. Morgan Healthcare Conference	CI
01-06	Abpro, Celltrion Say Solid Cancer Tumor Therapy Investigational New Drug Application Receives US FDA Clearance	MT
01-06	Abpro Holdings, Inc. and Celltrion, Inc. Announce U.S. FDA IND Clearance for Lead Multispecific Antibody Cancer Candidate ABP-102 / CT-P72	CI
01-02	Health Care Up on Anti-Obesity Drug Sales Outlook - Health Care Roundup	DJ
01-02	Celltrion, Inc. acquired Biopharmaceutical Manufacturing Facility in the United States from Eli Lilly and Company (NYSE : LLY).	CI

Chart Celltrion, Inc.

Duration

Period

A068270: Dynamic Chart

Company Profile

Celltrion Inc is a Korea-based company mainly engaged in the production and sale of bio pharmaceuticals. The Company operates its business through two segments. The Bio Pharmaceutical segment produces and sells protein therapeutics such as anticancer drugs. In addition, this Segment develops monoclonal antibodies(mABs) that are used to treat chronic autoimmune diseases such as arthritis and severe diseases such as breast and colon cancer. The Chemical Pharmaceutical segment is mainly engaged in the manufacture and sale of chemical drugs. In addition, the Segment sells bio drugs, and provides services such as data analysis. The Company's main products include liver and bowel medicines and other generics. The main products sold by the Company include autoimmune disease treatment agents, anti-malignant tumor drugs and other products. The Company sells its products in domestic and overseas markets such as Europe and the United States.

Employees

2,680

Sector

Biotechnology & Medical Research

More about the company